ACTG

Acacia Research Corp. Q1 2003 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2003. Acacia Research Corporation operates two distinct business groups under a single corporate entity: the CombiMatrix Group (life sciences, focusing on DNA/compound creation on semiconductor chips) and the Acacia Technologies Group (media technologies, focusing on Digital Media Transmission and V-chip patents). Following a December 2002 recapitalization, the company issues two classes of common stock intended to reflect the performance of these respective groups, though they remain part of one legal entity.

Key Financial Metrics

Segment Performance (Net Loss):

• CombiMatrix Group: $(5,173) (vs. $(3,586) in Q1 2002)
• Acacia Technologies Group: $(1,494) (vs. $(2,841) in Q1 2002)

Material Changes vs. Prior Period

• Revenue Composition Shift: Total revenue decreased slightly ($27k), but the source shifted. Q1 2003 saw $209k in product revenue (CombiMatrix sales to Japanese institutions) and $6k in license fees (Acacia Technologies DMT), compared to $249k in grant/contract revenue in Q1 2002.
• Expense Reductions: Operating expenses decreased by $1.5 million to $7.2 million. This was driven primarily by a significant drop in non-cash stock compensation ($1.4M in 2002 vs. $0.14M in 2003) and lower R&D spend ($2.3M vs. $2.7M).
• Investment Gains: The company recorded a $37k realized gain on short-term investments in Q1 2003, reversing a $553k loss in the same period in 2002.
• Minority Interests: Minority interest in losses dropped to $6k from $2.4M in 2002, as Acacia Research acquired 100% ownership of CombiMatrix Corporation in December 2002.

Outlook, Risks, and Management Commentary

Management Commentary:

• CombiMatrix: Highlighted sales of genomics microarray synthesizers to Keio University and Nihon Gene Research Laboratory in Japan. Received $1.7M in milestone payments from Roche, recorded as deferred revenue. R&D remains focused on commercialization obligations with Roche.
• Acacia Technologies: Initiated patent infringement litigation in February 2003 against ~40 internet content providers regarding DMT technology. The V-chip patent expires in July 2003; future revenue depends on DMT licensing success.

• Patent Expiration: The V-chip patent (a historical revenue driver) expires July 2003. Failure to replace this revenue with DMT licensing could materially harm the Acacia Technologies group.
• Litigation: Ongoing V-chip litigation resulted in a summary judgment against Acacia in September 2002; an appeal is pending. New DMT litigation is active but outcomes are uncertain.
• Liquidity: While cash and short-term investments total ~$49.7M, the company has a history of losses and expects to incur significant R&D and operating expenses. Future funding may be required.
• Capital Structure Risks: The two-class stock structure creates potential conflicts of interest and limits separate stockholder rights. Holders of one class are exposed to the liabilities of the other group.

Investor Verification Checklist

• Revenue Sustainability: Verify the timing and magnitude of future DMT license fee collections to offset the July 2003 V-chip patent expiration.
• Litigation Status: Monitor the outcome of the pending appeal regarding the V-chip summary judgment and the progress of the new DMT infringement suits.
• Roche Partnership: Assess the stability of the Roche agreement, which drives a majority of CombiMatrix's R&D and future revenue expectations.
• Cash Burn Rate: Review the trajectory of operating cash outflows ($4.6M used in Q1 2003) against the $49.7M cash balance to determine runway without additional financing.
• Deferred Revenue: Confirm the recognition schedule for the $12.2M in deferred revenues, particularly the $1.7M from Roche and $271k from Japanese sales.